Maintenance therapy in multiple myeloma
R Mihelic1, J L Kaufman, S Lonial
1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
Leukemia
|March 9, 2007
Summary
Maintenance therapy for multiple myeloma aims to prolong remission duration and survival. Effective strategies target minimal residual disease to improve event-free survival and overall survival, reducing treatment burden.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Multiple myeloma treatment has advanced, improving remission duration and overall survival (OS) with novel agents, immunotherapy, and chemotherapy.
- Despite initial success, most multiple myeloma patients eventually relapse, necessitating strategies to maintain remission.
- Maintenance therapy is crucial for prolonging remissions in minimal residual disease (MRD) after initial or high-dose therapy.
Purpose of the Study:
- To review current data on maintenance strategies in multiple myeloma.
- To evaluate the impact of maintenance therapy on event-free survival (EFS) and OS.
- To discuss future research directions for optimizing maintenance therapy.
Main Methods:
- Literature review of clinical trials and studies on multiple myeloma maintenance therapy.
- Analysis of data regarding the efficacy of various maintenance approaches in MRD settings.
- Synthesis of evidence on the impact of maintenance therapy on EFS and OS.
Main Results:
- Novel agents have significantly improved initial response rates but relapse remains common.
- Maintenance strategies are being explored to prolong remissions in patients with MRD.
- The effectiveness of maintenance therapy in improving EFS and OS is critical to avoid unnecessary costs and morbidity.
Conclusions:
- Effective maintenance therapy in multiple myeloma should target MRD to improve both EFS and OS.
- Careful evaluation of maintenance strategies is needed to balance efficacy with patient quality of life.
- Further clinical trials are essential to establish optimal maintenance protocols for multiple myeloma.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.